A sweeping investigation by the Maharashtra Food and Drug Administration (FDA) has brought to light an alarming pricing structure in private healthcare, revealing that private hospitals across the country are marking up basic medical consumables, surgical supplies, and critical implants by as much as 2,841% above wholesale and landed import rates.
While admitted patients and their families typically scrutinize room rent, doctor consultation fees, and branded prescription medicines, an enormous portion of the final discharge bill stems from unchecked consumable charges. The regulatory findings have triggered widespread outrage, prompting demands for immediate central intervention to shield citizens from severe out-of-pocket healthcare expenses.
Massive Margins on Syringes, IV Sets, and Critical Cardiac Implants
The price discrepancies detailed in the regulatory findings expose extreme profit margins on standard healthcare items. An ordinary intravenous (IV) infusion set, procured in the wholesale market for a mere ₹11, is billed to admitted patients at an inflated Maximum Retail Price (MRP) of ₹325—representing an astonishing 2,841% markup. Similarly, disposable sterile syringes procured for under ₹7 wholesale are routinely billed to unsuspecting patients at ₹60 each.
The artificial inflation expands even further in high-stakes interventions: life-saving, high-end medical devices including pacemakers, prosthetic heart valves, and intraocular eye lenses are being priced between 10 to 30 times their base import values before being billed to desperate families.
Regulatory Vacuum: Maharashtra FDA Flag Structural Flaws in DPCO 2013
Taking the issue to the public forum, Maharashtra FDA Commissioner Tukaram Munde classified the ongoing crisis as an entrenched structural regulatory failure that has persisted for over a decade and a half.
While the Drugs (Prices Control) Order (DPCO), 2013 strictly caps the pricing of essential bulk medications and formulations under the National List of Essential Medicines (NLEM), the vast majority of surgical consumables and advanced medical hardware remain entirely outside statutory pricing ceilings. Consequently, corporate hospitals and pharmaceutical distributors operate in an unregulated environment, freely determining inflated artificial MRPs to extract exorbitant trade margins without fear of legal penalization.
Domestic Manufacturers vs MNCs: Industry Voices Demand Trade Margin Rationalization
The exposure has created a sharp rift across medical manufacturing associations, though both domestic and multinational trade bodies now concede that current oversight is completely inadequate. Rajiv Nath, representing the Association of Indian Medical Device Industry (AiMeD), pointed out that ethical domestic manufacturers are severely harmed when hospitals favor brands that provide hyper-inflated retail price tags to pocket huge margins.
AiMeD has formally urged the Department of Pharmaceuticals and the National Pharmaceutical Pricing Authority (NPPA) to cap trade margins at 75% for high-volume consumables like syringes and IV sets, while setting a maximum 50% margin ceiling on high-end devices like pacemakers. Concurrently, industry bodies representing multinational medical device corporations have aligned with the Maharashtra FDA's demand, advocating for uniform, transparent guidelines that link consumer prices directly to the actual landed import cost.
